NPD Group: Online, home shopping sales of prestige fragrance up 10%
PORT WASHINGTON, N.Y. — The NPD Group announced on Monday that direct-to-consumer sales of U.S. prestige fragrance experienced double-digit growth in the 12 months ended February 2014.
During the 12-month period, direct-to-consumer sales of U.S. prestige fragrance grew 10% to $285 million. While a fraction of the $3 billion U.S. prestige fragrance market, the performance of products sold on department store web sites, in online-only beauty retailers, and through TV/home shopping retailers appears to be a bright spot for the industry, which saw 2% declines during the same time period.
“The desire to ‘try on’ a scent before committing isn’t about to go away, but there is real appeal for consumers in the immediacy of replenishing the supply of their favorite scents from the comfort of wherever they are,” stated Karen Grant, NPD’s VP and global industry analyst.
Gift sets led the pack, representing 46% of direct-to-consumer prestige fragrance sales in the United States, ahead of standalone juices, which accounted for 44% of sales. Gift set sales grew 9% compared with the 12 months ended February 2013.
Men’s fragrances represent a smaller portion of the sales than women’s in both prestige department stores and direct-to-consumer channels. However in both cases, men’s fragrances outperformed the women’s and the overall market in the 12 months ended February 2014. NPD’s BeautyTrends Direct showed a 19% increase in dollar sales of men’s prestige fragrances during this time.
According to NPD, fragrances sold in sizes of 5 ounces or larger grew 26% during this 12-month period versus 12% sales growth in prestige department stores.
“Offering consumers incentives and options that link the in-store experience with the convenience of purchasing direct is the best of both worlds. It is this type of seamless retailing that is providing manufacturers and retailers a world of new opportunities,” added Grant.
CVS/pharmacy launches new bill pay service for health insurance premiums
WOONSOCKET, R.I. — CVS/pharmacy announced on Monday that it is launching later this spring a new service, dubbed Bill Pay at CVS/pharmacy, to help customers manage their monthly health insurance premiums.
Members of participating health plans can bring their insurance bills to any one of CVS/pharmacy’s 7,600 stores across the United States to pay their premiums at no additional cost. CVS/pharmacy is the first national retail pharmacy to offer this service.
"Millions of Americans have enrolled in health insurance this year for the first time and we want to help with this transition by providing an easy way to pay their premiums in our stores," stated Josh Flum, SVP of retail pharmacy at CVS Caremark. "Providing customers with this level of unprecedented access to manage their insurance premiums is part of our commitment to delivering innovative solutions to help people on their path to better health."
CVS/pharmacy has partnered with InComm to facilitate bill payments at all cash registers in the pharmacy or at front checkout. Members of health plans that participate in Bill Pay at CVS/pharmacy will receive their monthly premium bills featuring a customer-specific barcode and instructions on how it may be used to pay their premium. CVS will scan the barcode and collect the member’s desired payment, which may be made using cash, credit card or debit card.
CVS/pharmacy also accepts insurance bill payments from members of health plans that are enrolled in MoneyGram’s bill payment service. Most CVS/pharmacy locations are equipped with MoneyGram phones or kiosks to facilitate a cash-only bill payment at a store’s front checkout.
Teva’s injunction on introduction of Mylan’s generic Copaxone denied
PITTSBURGH — Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva’s application for an injunction seeking to prevent Mylan’s launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court’s decision on Teva’s appeal. This is the second time that the Chief Justice has denied Teva’s request for such an injunction.
In March, the Supreme Court granted Teva’s petition for certiorari seeking clarification of the standard of review that appellate courts should apply when considering appeals relating to the construction of a patent claim. Oral argument is expected to be heard in the fall of 2014.
"We look forward to introducing the first gene treatment for multiple sclerosis patients in the U.S. at market formation," stated Heather Bresch, Mylan CEO. "Mylan remains eligible to receive approval from the U.S. Food and Drug Administration on May 25, 2014."